Key Highlights

  • Therma Bright (TSXV:THRM) fell 16.67% to a quoted CAD 0.025, with a market Capitalization of CAD 1.84 million and a 14-period RSI of 19.41.
  • Therma Bright sells the VenoWave device through U.S. distributors and holds an interest in Inretio, which is developing the PREVA neuro-thrombectomy system for stroke.
  • On October 23, 2026, the company proposed a non-brokered private Placement at a price above the current quote, after settling Debt with shares in July.
  • No company-specific catalyst was identified in the disclosures reviewed. The disclosures reviewed do not explain the day’s decline, and the financing, VenoWave sales and the Inretio trial timeline are the main items to monitor.

Introduction

Therma Bright Inc. (TSXV:THRM) is a medical technology company listed on the TSX Venture Exchange. Its shares fell 16.67% to CAD 0.025 on November 3, 2026, with a market capitalization of CAD 1.84 million and a 14-period RSI of 19.41. A one-day decline of 16.67% is large, and the question for investors is how it relates to the company’s recent financing and its product rollout.

Catalyst and Latest Updates

Therma Bright is a medical technology company. Its VenoWave product has been sold in the United States through distributors, including Horizon Health USA, which placed an initial order in March 2026 and a follow-on order in May, and Gen-X Med, a Texas distributor that placed follow-on orders in January and again by June. The company said in June that it was preparing its Supply chain for higher sales volume. Through its interest in Inretio, it is also involved in the PREVA neuro-thrombectomy system for stroke, which completed the first cohort of a first-in-human study in February with a U.S. FDA trial targeted for 2026.

Financing is the most recent theme. On July 30, 2026, the company Issued Shares to settle debt, and on October 23 it proposed a non-brokered private placement of shares, priced above the current quote, to raise a modest amount of capital.

No company-specific catalyst was identified in the disclosures reviewed. The financing announcement preceded the session by several days, and nothing in the disclosures reviewed explains the decline on November 3.

Volume, Data and Context

A price of CAD 0.025 is a very low nominal level where the smallest price increment is a large percentage of the quote, so a few trades can produce moves of the size seen here. The proposed placement price is above the current quote, a comparison taken from the company’s announcement and not from the data provided.

The market capitalization of CAD 1.84 million is the total value the market places on the outstanding shares at the quoted price. At CAD 1.84 million, Therma Bright is a nano-cap company, and its Market Value is small relative to the cost of developing and selling medical devices. Market value does not show whether shares are expensive or inexpensive.

The 14-period RSI of 19.41 indicates strongly negative recent momentum. RSI, or Relative Strength Index, compares the size of recent gains with the size of recent losses, and readings at the low end of its scale are conventionally described as oversold. The timeframe of the indicator was not specified. A low reading describes how the price has behaved; it does not explain the weakness, and it does not signal that a Reversal is coming. The session’s decline of 16.67% is consistent with that momentum but does not establish its cause.

Taken together, the figures describe a nano-cap medical device company whose shares fell sharply in one session, with a financing recently proposed and no confirmed cause for the decline.

Risks and What to Watch

Financing and dilution are the main risks. A company of this size depends on frequent small Equity raises and share-for-debt settlements, which increase the share count. A completed placement would add shares, and the proposed price sits above the current quote.

Commercial risk applies to VenoWave. Sales depend on a small number of distributors, and repeat orders are not guaranteed.

Regulatory and clinical risk apply to the Inretio platform. The company’s interest depends on trial progress, FDA decisions and the funding of Inretio itself.

Liquidity is thin at this price level, so prices can move sharply on small volumes.

Investors should watch for the closing and terms of the private placement, further VenoWave orders, progress on the PREVA U.S. FDA trial, any additional debt settlements and the company’s quarterly filings.

Outlook

The company has said it is preparing for higher VenoWave volumes and that the PREVA platform is moving toward a U.S. trial. These are company statements rather than guarantees, and the price, market capitalization and RSI do not measure progress.

Where Things Stand

Therma Bright (TSXV:THRM) fell 16.67% to a quoted CAD 0.025, with a market capitalization of CAD 1.84 million and an RSI of 19.41. What is known is that momentum has been strongly negative, that the shares fell 16.67% on the session and that a private placement was proposed on October 23. What remains uncertain is what caused the decline, since the disclosures reviewed do not explain it. The placement closing and further order announcements would give the clearest evidence. The figures should be treated as a snapshot, since the time of the data was not provided.